Pharma Equity Group A/S
PEG.CO · CPH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -18.95 | 0.15 | -1.15 | -0.04 |
| FCF Yield | -11.26% | -3.59% | -18.80% | -9.17% |
| EV / EBITDA | -10.10 | -19.78 | 8.48 | 6.89 |
| Quality | ||||
| ROIC | -33.07% | -33.53% | 4.39% | -2.35% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.62 | -0.83 | -0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -36.92% | -480.97% | -37.58% | 78.91% |
| Safety | ||||
| Net Debt / EBITDA | -0.45 | -1.05 | 5.06 | 3.13 |
| Interest Coverage | -4.29 | -16.19 | 3.04 | -2.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 480.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,344.79 | -7,757.01 | 0.00 | 0.00 |